Result of Scrip Dividend Alternative Offer and Sha
Amlin Plc
AMLIN PLC ('Amlin')
RESULT OF SCRIP DIVIDEND ALTERNATIVE OFFER AND SHARE CAPITAL UPDATE
The Scrip Dividend Alternative to Amlin's interim dividend for 2003 of 0.85p per
share was accepted in respect of 71,651,043 shares, representing approximately
18.4% of Amlin's issued share capital on the dividend record date of 19
September 2003. At the reference price of 137.5p per share, those electing for
the scrip dividend are entitled to the issue of a total of 442,798 new ordinary
shares of 25p each fully paid, ranking, when issued, pari passu in all respects
with Amlin's existing shares.
Application is being made to the UK Listing Authority and the London Stock
Exchange for these additional shares to be admitted to the Official List and to
trading. It is expected that such listing will become effective and that
dealings in the additional shares will commence on 3 November 2003.
Following the issue of the Scrip Dividend Alternative shares, and recent
exercises of executive share options, the issued share capital of Amlin will be
390,788,250 ordinary shares of 25p each.
28 October 2003
Enquiries:
Charles Pender 020 7746 1008
Secretary
Amlin plc
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.